CLINUVEL’s Director of Global Operations, Lachlan Hay, presented at the Capital Markets Briefing that took place in Sydney earlier this month. He shed light on how CLINUVEL’s distribution model differs from traditional models, and provided an update on facilitating treatment for adolescent erythropoietic protoporphyria (EPP) patients.
The full slide deck is available on clinuvel.com.